uniQure (QURE) Stock Price, News & Analysis

Company Overview

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement. The company also has a clinical-stage pipeline that has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as other programs targeting neurological and neuromuscular disorders.

The company was founded in the Netherlands in 1998 as Amsterdam Molecular Therapeutics and adopted the uniQure name in 2012. It maintains operations in the United States and Europe, with research, development and manufacturing capabilities serving its global programs. uniQure is headquartered in Lexington, Massachusetts, and its ordinary shares trade on the Nasdaq Global Select Market under the symbol QURE.

Key Stats

• Today's Range: $22.87 to $24.09
• 50-Day Range: $20.97 to $51.05
• 52-Week Range: $8.73 to $51.72
• Volume: 552,793 shs
• Average Volume: 2.41 million shs
• Market Capitalization: $1.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.25
• Consensus Rating: Moderate Buy

uniQure Stock Analysis - MarketRank™

uniQure scored higher than 66% of companies evaluated by MarketBeat, and ranked 309th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

uniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 12 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

uniQure has a consensus price target of $53.25, representing about 128.9% upside from its current price of $23.27.

Amount of Analyst Coverage

uniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for uniQure are expected to grow in the coming year, from ($3.82) to ($3.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of uniQure is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of uniQure is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

uniQure has a P/B Ratio of 7.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.19% of the float of uniQure has been sold short.

Short Interest Ratio / Days to Cover

uniQure has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in uniQure has recently increased by 0.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

uniQure does not currently pay a dividend.

Dividend Growth

uniQure does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

uniQure has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for uniQure this week, compared to 10 articles on an average week.

Search Interest

13 people have searched for QURE on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, uniQure insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.65% of the stock of uniQure is held by insiders.

Percentage Held by Institutions

78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QURE
• CIK: 1590560
• Web: www.uniqure.com
• Phone: (120) 240-6000
• Fax: 31-20-566-9272
• Employees: 221
• Year Founded: 1868

Price Target and Rating

• Average Price Target for uniQure: $53.25
• High Price Target: $80.00
• Low Price Target: $28.00
• Potential Upside/Downside: +125.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.97 million
• Net Margins: -1,350.73%
• Pretax Margin: -1,313.04%
• Return on Equity: -111.96%
• Return on Assets: -29.01%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 10.01
• Quick Ratio: 10.01

Sales & Book Value

• Annual Sales: $16.10 million
• Price / Sales: 101.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.19 per share
• Price / Book: 7.39

Miscellaneous

• Outstanding Shares: 69,370,000
• Free Float: 66,140,000
• Market Cap: $1.64 billion
• Optionable: Optionable
• Beta: 1.06